These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1096899)

  • 21. 3-O-methyldopa blocks dopa metabolism in rat corpus striatum.
    Reches A; Fahn S
    Ann Neurol; 1982 Sep; 12(3):267-71. PubMed ID: 7137962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal dopaminergic system in nephrotic syndrome and after remission.
    Pestana M; Jardim H; Afonso C; Serrão P; Santos N; Guerra L; Soares-da-Silva P
    Nephrol Dial Transplant; 1998 Oct; 13(10):2559-62. PubMed ID: 9794559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Control of on/off phenomenon by continuous intravenous infusion of levodopa.
    Quinn N; Parkes JD; Marsden CD
    Neurology; 1984 Sep; 34(9):1131-6. PubMed ID: 6540399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dosage form design for improvement of bioavailability of levodopa III: Influence of dose on pharmacokinetic behavior of levodopa in dogs and Parkinsonian patients.
    Sasahara K; Nitanai T; Habara T; Morioka T; Nakajima E
    J Pharm Sci; 1980 Dec; 69(12):1374-8. PubMed ID: 7463319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microdialysis-HPLC for plasma levodopa and metabolites monitoring in parkinsonian patients.
    Dethy S; Laute MA; Van Blercom N; Damhaut P; Goldman S; Hildebrand J
    Clin Chem; 1997 May; 43(5):740-4. PubMed ID: 9166225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biochemical effects of chronic L-dopa treatment in rats: implications for emergence of tolerance phenomena in patients with Parkinson's disease.
    Melamed E; Globus M; Rosenthal J; Uzzan A
    Adv Neurol; 1987; 45():507-10. PubMed ID: 3825730
    [No Abstract]   [Full Text] [Related]  

  • 27. [Experience with the use of parlodel in the treatment of Parkinson patients].
    Stoliarova LG; Kadykov AS; Shvedkov VV; Pivovarova VM
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1986; 86(2):219-22. PubMed ID: 3705825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimization of the hydrolysis of conjugated L-DOPA, dopamine and dihydroxyphenylacetic acid in human urine for assay by high-performance liquid chromatography with electrochemical detection.
    Tuomainen P; Männistö PT
    Eur J Clin Chem Clin Biochem; 1997 Mar; 35(3):229-35. PubMed ID: 9127745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro.
    Asanuma M; Miyazaki I; Diaz-Corrales FJ; Shimizu M; Tanaka K; Ogawa N
    Neurol Res; 2005 Jul; 27(5):533-9. PubMed ID: 15978181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serotonergic neurones are not involved in action of L-dopa in Parkinson's disease.
    Melamed E; Hefti F; Liebman J; Schlosberg AJ; Wurtman RJ
    Nature; 1980 Feb; 283(5749):772-4. PubMed ID: 6101905
    [No Abstract]   [Full Text] [Related]  

  • 31. L-dopa treatment of Parkinson's disease: a ten-year follow up study.
    Bauer RB; Stevens C; Reveno WS; Rosenbaum H
    J Am Geriatr Soc; 1982 May; 30(5):322-5. PubMed ID: 7077008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment.
    Karoum F; Chuang LW; Eisler T; Calne DB; Liebowitz MR; Quitkin FM; Klein DF; Wyatt RJ
    Neurology; 1982 May; 32(5):503-9. PubMed ID: 6803190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient.
    Evans MA; Broe GA; Triggs EJ; Cheung M; Creasey H; Paull PD
    Neurology; 1981 Oct; 31(10):1288-94. PubMed ID: 7202139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Abnormal movements of patients with Parkinsonism treated with L-dopa and anomalies of dopamine metabolism].
    Lhermitte F; Rosa A; Comoy E
    Rev Neurol (Paris); 1977 Jan; 133(1):3-11. PubMed ID: 847319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. On/off syndrome in Parkinson's disease and intravenous levodopa.
    Clough CG
    Lancet; 1982 Oct; 2(8301):765. PubMed ID: 6125830
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical pharmacokinetics of levodopa in parkinson's disease.
    Bianchine JR; Shaw GM
    Clin Pharmacokinet; 1976; 1(5):313-38. PubMed ID: 797502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats.
    Rose S; Jenner P; Marsden CD
    Mov Disord; 1988; 3(2):117-25. PubMed ID: 3221899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
    Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
    J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dosage form design for improvement of bioavailability of levodopa II: bioavailability of marketed levodopa preparations in dogs and parkinsonian patients.
    Sasahara K; Nitanai T; Habara T; Morioka T; Nakajima E
    J Pharm Sci; 1980 May; 69(3):261-5. PubMed ID: 7381698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and pharmacological evaluation of the effects of piribedil in patients with parkinsonism.
    McLellan DL; Chalmers RJ; Johnson RH
    Acta Neurol Scand; 1975 Jan; 51(1):74-82. PubMed ID: 1091122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.